ResMedMEX:RMD 99 OCF Yield % is 6.51 as of Jun. 28, 2026, which is 105% above its 10-year median of 3.18. GuruFocus rates MEX:RMD with a GF Score™ of 99/100 and a GF Value™ of MXN5,059.75 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 852 Medical Devices & Instruments companies, ResMed ranks better than 73.24% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
The historical rank and industry rank for ResMed's OCF Yield % or its related term are showing as below:
MEX:RMD'
s OCF Yield % Range Over the Past 10 Years
Min: 0.99 Med: 3.18 Max: 6.88
Current: 6.51
During the past 13 years, the highest OCF Yield % of ResMed was 6.88%. The lowest was 0.99%. And the median was 3.18%.
MEX:RMD's OCF Yield % is ranked better than 73.24% of 852
companies
in the Medical Devices & Instruments industry
Industry Median: 1.785
vs MEX:RMD: 6.51
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
ResMed OCF Yield % Related Terms
ResMed OCF Yield % Historical Data
* Premium members only.
The historical data trend for ResMed's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, ResMed's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ResMed OCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ResMed's OCF Yield % distribution charts can be found below:
* The bar in red indicates where ResMed's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ResMed (MEX:RMD) has a OCF Yield % of 6.51 as of Jun. 28, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on ResMed and its competitors. This is 105% above median its historical median of 3.18. Over the past decade, ResMed's OCF Yield % has ranged from 0.99 to 6.88. According to the industry distribution chart, ResMed ranks #228 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 26.8%.
Is ResMed's OCF Yield % too high?
ResMed's current OCF Yield % of 6.51 is 105% above median its 10-year median of 3.18. Over the past 10 years, this metric has ranged from a low of 0.99 to a high of 6.88. The Medical Devices & Instruments industry median OCF Yield % is 1.79. ResMed's value of 6.51 is 264.7% above this industry median. Based on the distribution chart, ResMed ranks #228 out of 852 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, ResMed has a GF Score™ of 99/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ResMed's OCF Yield % compare to MDLN and WST?
According to the Medical Devices & Instruments industry distribution chart, ResMed ranks #228 out of 852 companies for OCF Yield %. This puts ResMed in the upper half of its industry. The industry median OCF Yield % is 1.79. ResMed's value of 6.51 is 264.7% above this benchmark. Historically, ResMed's own OCF Yield % has ranged from 0.99 to 6.88 over the past decade. While the company's 10-year median is 3.18 vs. the industry median of 1.79, ResMed has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Medical Devices & Instruments company?
The median OCF Yield % among Medical Devices & Instruments companies is 1.79, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ResMed's current OCF Yield % of 6.51 is 264.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on ResMed and its competitors. For the Medical Devices & Instruments industry, the median OCF Yield % is 1.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ResMed's current OCF Yield % is 6.51, which is 105% above median its own 10-year median of 3.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ResMed stock overvalued right now?
Based on GuruFocus' analysis, ResMed (MEX:RMD) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN5,059.75, compared to a current price of MXN3,716.10 — trading 26.6% below its estimated fair value. The current OCF Yield % is 6.51, which is 105% above median its 10-year median of 3.18 and 264.7% above the Medical Devices & Instruments industry median of 1.79. ResMed's overall GF Score™ is 99/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For ResMed (MEX:RMD), the current OCF Yield % is 6.51 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ResMed (MEX:RMD) Overvalued in 2026?
Based on GuruFocus' analysis, ResMed stock appears to be undervalued.
The current stock price of MXN3,716.10 is trading 26.6% below its estimated GF Value™ of MXN5,059.75.
GuruFocus considers ResMed to be Modestly Undervalued.
Key valuation signals for MEX:RMD:
OCF Yield %: 6.51 (105% above median its 10-year median of 3.18)
GF Value™: MXN5,059.75 vs. price of MXN3,716.10 (26.6% below fair value)
Industry Position: 264.7% above the Medical Devices & Instruments median (#228 of 852)
No single metric tells the full story. See the MEX:RMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
99GF Score
Get the complete analysis for MEX:RMD
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:RMD has been successfully added to your 
